Misonix BoneScalpel(TM) Cited As “A Game Changer” Product
FARMINGDALE, N.Y., Nov. 28, 2012 /PRNewswire/ — Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, was prominently referred to in an article published by Becker’s Orthopedic & Spine Review on November 16, 2012, entitled “5 Spine Experts on Most Exciting Technology for Spinal Surgery.”
In the article, the following question was asked: “What technology have you been most impressed with over the past year?” Isador Lieberman, MD, Spine Surgeon, Texas Back Institute, Plano, Texas replied: “The ultrasonic BoneScalpel(TM) developed and distributed by Misonix, Inc., in the words of a recent fellow of mine, is ‘a game changer.’ As I have gained experience with it I have been able to take advantage of its atraumatic method of osteotomising bone for facetectomies, Smith Petersen osteotomies, pedicle subtraction osteotomies and even cervical corpectomies. The device is safe, efficient and provides for a precise cut. It has dramatically enhanced my ability to decompress the spine or release the spine in a less invasive fashion.”
Becker’s Orthopedic & Spine Review is a leading resource offering news and analysis on business and legal issues relating to orthopedic and spine practices and is widely read by clinical practitioners, service providers and medical device manufacturers.
The BoneScalpel is a novel ultrasonic osteotome used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively bloodless and clean. Loss of viable bone is minimal and controllable. The BoneScalpel has been used extensively for bone removal in the cervical, thoracic and lumbar spine, including deformity surgery.
“We are excited by yet another endorsement of the contribution being made to advanced spinal surgery by the Misonix BoneScalpel,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “Being named one of the most exciting technologies for spinal surgery is a great distinction recognizing our BoneScalpel as a unique product that provides the surgeon with more safety, a better cut, greater visibility from less blood loss and an overall faster procedure. We are privileged to provide state of the art spine surgery technology to Dr. Lieberman and his colleagues throughout the world.”
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contacts: Misonix Contact: Lytham Partners, LLC Richard Zaremba Robert Blum, Joe Dorame, Joe Diaz 631-694-9555 602-889-9700 firstname.lastname@example.org email@example.com
SOURCE Misonix, Inc.